

Jack Ansell

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2987816/jack-ansell-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

10,042
citations

21
h-index

57
g-index

57
ext. papers

11,651
ext. citations

6
avg, IF

5.33
L-index

#	Paper	IF	Citations
51	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
50	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 160S-198S	5.3	1648
49	The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , 2004 , 126, 204S-233S	5.3	852
48	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2597-2604	15.1	291
47	American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. <i>Blood Advances</i> , 2018 , 2, 3257-3291	7.8	199
46	Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , 2015 , 170, 141-8, 148.e1	4.9	152
45	Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). <i>Journal of Thrombosis and Thrombolysis</i> , 2007 , 23, 83-91	5.1	108
44	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017 , 194, 132-140	4.9	104
43	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). <i>Journal of the American Heart Association</i> , 2018 , 7,	6	104
42	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014 , 167, 735-42.e2	4.9	80
41	New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. <i>Circulation</i> , 2012 , 125, 165-70; discussion 170	16.7	56
40	Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>Circulation</i> , 2014 , 129, 2005-12	16.7	55
39	Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. <i>American Heart Journal</i> , 2014 , 168, 160-7	4.9	53
38	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2015 , 169, 25-30	4.9	51
37	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2017 , 189, 40-47	4.9	40
36	Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017 , 3, 192-197	4.6	38
35	The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 824-30	2.9	36

34	Reversal agents in development for the new oral anticoagulants. <i>Postgraduate Medicine</i> , 2014 , 126, 19-24	4.7	32
33	Warfarin versus new agents: interpreting the data. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 221-8	3.1	29
32	Current options in the prevention of thromboembolic disease. <i>Drugs</i> , 2004 , 64 Suppl 1, 1-5	12.1	28
31	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). <i>American Journal of Cardiology</i> , 2017 , 119, 1590-1595	3	26
30	STABLE results: warfarin home monitoring achieves excellent INR control. <i>American Journal of Managed Care</i> , 2014 , 20, 202-9	2.1	20
29	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017 , 130, 449-456	2.4	16
28	Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019 , 3, 789-796	7.8	15
27	Disease understanding in patients newly diagnosed with atrial fibrillation. <i>Heart</i> , 2018 , 104, 494-501	5.1	15
26	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 525-534	16.2	13
25	Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. <i>Blood</i> , 2021 , 137, 115-125	2.2	12
24	Bleeding and clotting in hereditary hemorrhagic telangiectasia. <i>World Journal of Clinical Cases</i> , 2015 , 3, 330-7	1.6	11
23	Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition. <i>Annals of Pharmacotherapy</i> , 2015 , 49, 113-24	2.9	10
22	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2016 , 181, 145-152	4.9	10
21	A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators.. <i>Blood</i> , 2006 , 108, 574-574	2.2	9
20	A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation. <i>Blood Advances</i> , 2019 , 3, 1638-1646	7.8	9
19	A Novel Whole Blood Point-of-Care Coagulometer to Measure the Effect of Direct Oral Anticoagulants and Heparins. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 259-263	5.3	9
18	Thrombophilic Evaluation in Patients with Acute Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 107-120	3.9	7
17	Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. <i>Clinical Cardiology</i> , 2017 , 40, 746-751	3.3	7

16	Point-of-care patient self-monitoring of oral vitamin K antagonist therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 339-41	5.1	6
15	Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). <i>Thrombosis and Haemostasis</i> , 2014 , 112, 841	7	5
14	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2020 , 226, 85-93	4.9	4
13	Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting Time. <i>Blood</i> , 2018 , 132, 987-987	2.2	4
12	Defining Minimum Necessary Anticoagulation-Related Communication at Discharge: Consensus of the Care Transitions Task Force of the New York State Anticoagulation Coalition. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2018 , 44, 630-640	1.4	3
11	Correction to lepirudin dosage in table 1 of Direct Thrombin Inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 718-718	3.8	2
10	New targets for anticoagulation and future perspectives. <i>Current Drug Discovery Technologies</i> , 2012 , 9, 150-5	1.5	2
9	Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. <i>European Heart Journal</i> , 2021 ,	9.5	2
8	Target specific oral anticoagulants in the management of thromboembolic disease in the elderly. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 203-11	5.1	1
7	Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect. <i>Blood</i> , 2020 , 136, 24-24	2.2	1
6	Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic.. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2022 , 48, 214-214	1.4	0
5	Anticoagulant Management of Atrial Fibrillation In the United States: Findings From a Large National Database of Clinical Test Results (Quest Diagnostics Health Trends Report).. <i>Blood</i> , 2010 , 116, 1103-1103	2.2	0
4	Integrating electronic health records in the delivery of optimized anticoagulation therapy. <i>Annals of Pharmacotherapy</i> , 2015 , 49, 125-6	2.9	
3	Point-Counter Point: Low Intensity vs Standard Intensity Oral Anticoagulation for Long-Term Prevention of Venous Thromboembolism Recurrence. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 21, 49-49	5.1	
2	Indications for Inferior Vena Cava (IVC) Filter Placement - Assessing Compliance with Accepted Standards Set by Two Professional Societies. <i>Blood</i> , 2010 , 116, 2553-2553	2.2	
1	Indirect Comparison Of Dabigatran, Rivaroxaban and Apixaban For Venous Thromboembolic Disease. <i>Blood</i> , 2013 , 122, 3640-3640	2.2	